According to IMS Health the Institute brings together the public and private sectors, applying “analytics-driven approaches,” based on real-world evidence for disease modeling and insights.
“The IMS Institute for Healthcare Informatics provides key policy setters and decision makers in the global health sector with unique and transformational insights into healthcare dynamics derived from granular analysis of information,” Tor Constantino, an IMS Health spokesperson told Outsourcing-Pharma.com.
“It is a research-driven entity with a worldwide reach that collaborates with external healthcare experts from across academia and the public and private sectors to objectively apply IMS Health’s proprietary global information and analytical assets.”
The new institute in Asia is the first collaboration platform in the region, said Constantino, and it aims to improve quality of care and reduce healthcare costs in the area.
Constantino explained this will be achieved “by empowering decision makers with the insights and tools they need, specific to the unique needs within the Asian healthcare market.”
Ultimately, this means patients will receive “the best available treatment at the right time with the right level of care to improve their quality of life and get better sooner,” he added.
The Institute will also work on improving treatment outcomes for some of the most pressing diseases in the region such as diabetes and stroke.
While the merger of Quintiles and IMS Health is still underway, Constantino said it’s expected that the IMS Institute will continue to operate in its current capacity after the completion of the merger.
The merger was announced in May of this year.